Pro odborníky

TOP TEN ASTRO 2014

1. Randomized Phase III Trial of Adjuvant Androgen Deprivation in Combination With High-Dose Conformal Radiation Therapy in Intermediate- and High-Risk Localized Prostate Cancer.

2. Initial Results of a Phase III Randomized Study of High Dose 3D-CRT_IMRT versus Standard Dose 3D-CRT_IMRT in Patients Treated for Localized Prostate Cancer_RTOG 0126.

3. Mature Survival Data from RTOG 9802 - A Phase III Study of Radiation Therapy With or Without Procarbazine, CCNU, and Vincristine for Adult Patients with LGG.

4. Local Excision Versus TME in Patients with Good Response After Neoadjuvant CHRT for T2-T3 Low Rectal Cancer Preliminary Results of the GRECCAR 2 Randomized Phase III Trial.

5. Definitive AHF CHRT Versus Neoadjuvant AHF-CHRT and Surgery for Patients With Operable Stage IIIA(N2)_Selected IIIB NSCLCancer Following Induction CHT.

6. Long-Term Toxicity and Cosmetic Results of Partial Versus Whole Breast Irradiation_10-Year Results of a Phase III APBI Trial.

7. Consensus Guidelines for Delineation of CTV for IMRT in Postoperative Treatment of Endometrial and Cervical Cancer- An Update.

8. Role of Radiation Therapy in Inducing Antigen Specific Antitumor Immune Responses When Combined With Anti-PD1 Checkpoint.

9. A Unifying Method to Derive Electron Density From MRI for Radiation Therapy Treatment Planning.

10. First Clinical Implementation of Electromagnetic Transponder-Guided MLC Tracking.

VÝZNAMNÉ RETROSPEKTIVNÍ STUDIE A METAANALÝZY

1.Early-Stage Hodgkin Disease: The Utilization of Radiation Therapy and Its Impact on Overall Survival

2. New Aspects Regarding the Adjuvant Radiation Therapy to the Internal Mammary and Medial Lymph Nodes in Breast Cancer: A Meta-analysis of Randomized Trials

3.Simple Clinical Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy in Lung Cancer: A Pooled Analysis of 70 Studies

4. Impact on Survival of Brachytherapy in Inoperable Endometrial Cancer_The (SEER) Experience From 2004-2010.

5. Radiation Therapy for Clinically Node-Positive Prostate Cancer and Survival_Results from the National Cancer Data Base.

6. Time Will Tell_Is 60 Gy in 3 Fractions the Optimal SBRT Schedule for Stage I NSCLC...

7. Second Malignancies after Adjuvant Radiotherapy for Early Stage Breast Cancer: Is There an Increased Risk with the Addition of Regional Radiotherapy?

8. Long term Impact of AD Therapy on Cardiovascular Morbidity after RT for Clinically Localized Prostate Cancer

9. Cardiovascular Diseases After Hodgkin Lymphoma Treatment_35-Year Disease Risk and Sequence of Events.

10. Impact of Approximated Biological Subtype on Locoregional Recurrence in Women With Node-Negative Breast Cancer Treated With Mastectomy.

6